Skip to main content

Animations

MJFF Publications

8671 - 8680 of 8808 Results
Title
Year
  • Year
  • 2014
  • 2017
  • 2020
  • 2015
  • 2018
  • 2018
  • 2023
  • 2015
  • 2019
  • 2020
  • Summary Details
    OPEN
    Title: Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.nbd.2013.12.011
    Citation Count: 81
  • Summary Details
    OPEN
    Title: Integrating Next-Generation Genomic Sequencing and Mass Spectrometry To Estimate Allele-Specific Protein Abundance in Human Brain
    Journal Name: Journal of Proteome Research
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acs.jproteome.7b00324
    Citation Count: 55
  • Summary Details
    OPEN
    Title: Probabilistic Modelling of Gait for Robust Passive Monitoring in Daily Life
    Journal Name: IEEE Journal of Biomedical and Health Informatics
    Publisher: Institute of Electrical and Electronics Engineers (IEEE)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1109/jbhi.2020.3037857
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Neuroimaging and clinical predictors of fatigue in Parkinson disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2015.11.029
    Citation Count: 36
  • Summary Details
    OPEN
    Title: Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease
    Journal Name: Journal of Tissue Engineering and Regenerative Medicine
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/term.2698
    Citation Count: 58
  • Summary Details
    RESTRICTED
    Title: A Phase 2a study of nilotinib in patients with advanced and early Parkinson’s disease. Study design (P5.068)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.90.15_supplement.p5.068
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Network connectivity and local transcriptomic vulnerability underpin cortical atrophy progression in Parkinson’s disease
    Journal Name: NeuroImage: Clinical
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nicl.2023.103523
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26251
    Citation Count: 106
  • Summary Details
    OPEN
    Title: No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson's disease
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2019.11.006
    Citation Count: 14
  • Summary Details
    RESTRICTED
    Title: Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27991
    Citation Count: 23
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.